Abstract
Chronic obstructive pulmonary disease (COPD) is a common and disabling disease and the third leading cause of global mortality behind ischemic heart disease and stroke. Acute exacerbations of COPD accelerate lung function decline affecting the quality of life of COPD patients and moreover, remain the major contributors to morbidity and mortality of these patients. Cardiovascular comorbidities are prevalent in COPD patients and of great importance since they have a negative impact on patients’ health status. During the past few years there is an increasing interest in potential molecules that can be measured accurately and reproducibly and that can be used in COPD as biomarkers to predict clinical important outcomes such as exacerbations, hospitalizations and mortality. Such molecules have been successfully used in cardiovascular diseases and therefore, cardiac biomarkers have attracted attention for their potential use in COPD. The present review summarizes the available evidence for the use of the most important cardiac biomarkers in the evaluation of COPD severity, outcomes and management.
Keywords: Cardiac biomarkers, Chronic obstructive pulmonary disease, Acute exacerbations of chronic obstructive pulmonary disease, Comorbidities, Copeptin, B-natriuretic peptide, Adrenomedullin, Troponin T.
Current Topics in Medicinal Chemistry
Title:Cardiac Biomarkers in the Identification of Future Risk in Chronic Obstructive Pulmonary Disease
Volume: 16 Issue: 14
Author(s): Kathleen Jahn, Eleni Papakonstantinou and Daiana Stolz
Affiliation:
Keywords: Cardiac biomarkers, Chronic obstructive pulmonary disease, Acute exacerbations of chronic obstructive pulmonary disease, Comorbidities, Copeptin, B-natriuretic peptide, Adrenomedullin, Troponin T.
Abstract: Chronic obstructive pulmonary disease (COPD) is a common and disabling disease and the third leading cause of global mortality behind ischemic heart disease and stroke. Acute exacerbations of COPD accelerate lung function decline affecting the quality of life of COPD patients and moreover, remain the major contributors to morbidity and mortality of these patients. Cardiovascular comorbidities are prevalent in COPD patients and of great importance since they have a negative impact on patients’ health status. During the past few years there is an increasing interest in potential molecules that can be measured accurately and reproducibly and that can be used in COPD as biomarkers to predict clinical important outcomes such as exacerbations, hospitalizations and mortality. Such molecules have been successfully used in cardiovascular diseases and therefore, cardiac biomarkers have attracted attention for their potential use in COPD. The present review summarizes the available evidence for the use of the most important cardiac biomarkers in the evaluation of COPD severity, outcomes and management.
Export Options
About this article
Cite this article as:
Jahn Kathleen, Papakonstantinou Eleni and Stolz Daiana, Cardiac Biomarkers in the Identification of Future Risk in Chronic Obstructive Pulmonary Disease, Current Topics in Medicinal Chemistry 2016; 16 (14) . https://dx.doi.org/10.2174/1568026616666150930120233
DOI https://dx.doi.org/10.2174/1568026616666150930120233 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Bacterial Cell Wall Compounds as Promising Targets of Antimicrobial Agents II. Immunological and Clinical Aspects
Current Drug Targets Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
Recent Patents on Cardiovascular Drug Discovery Pharmacogenomics: Integration into Drug Discovery and Development
Current Topics in Medicinal Chemistry Biomedical Applications of Superparamagnetic Nanoparticles in Molecular Scale
Current Organic Chemistry Lock Stock and Barrel of Wound Healing
Current Pharmaceutical Design Pathophysiology of Post-Operative Low Cardiac Output Syndrome
Current Vascular Pharmacology Use of Paediatric Xylometazoline Nasal Drop is not a Child’s Play in Hypertensive Patients on Bisoprolol: A Case Report
Current Drug Safety Risk Factors and Potential Preventive Measures for Vascular Disease Progression in Hemodialysis Patients
Vascular Disease Prevention (Discontinued) Understanding the Role of Aldose Reductase in Ocular Inflammation
Current Molecular Medicine Ibogaine in the Treatment of Substance Dependence
Current Drug Abuse Reviews Reactive Oxygen-Induced Cardiac Intracellular Pathways During Ischemia and Reperfusion
Current Signal Transduction Therapy Diminished Renal Function and the Incidence of Heart Failure
Current Cardiology Reviews Crosstalk between Behavior and Immune System During the Prodromal Stages of Alzheimer`s Disease
Current Pharmaceutical Design Fenofibrate: Metabolic and Pleiotropic Effects
Current Vascular Pharmacology The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism Lipid-Lowering Therapies for Atherosclerosis: Statins, Fibrates, Ezetimibe and PCSK9 Monoclonal Antibodies
Current Medicinal Chemistry Socioeconomic Position and Type 2 Diabetes Mellitus in Europe 1999- 2009: a Panorama of Inequalities
Current Diabetes Reviews Cardiovascular Complications in Inflammatory Bowel Disease
Current Drug Targets Development of Standardized <i>Cyanthillium cinereum</i> (L.) H.Rob. Extract and Determination of its Biological Activities
The Natural Products Journal Cathinone Neurotoxicity (“The “3Ms”)
Current Neuropharmacology